Loading...

Zura Bio Limited

94E.FXETRA
Healthcare
Biotechnology
1.18
0.04(3.51%)

Zura Bio Limited (94E.F) Stock Overview

Explore Zura Bio Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.6/100

Key Financials

Market Cap73M
P/E Ratio-1.99
EPS (TTM)$-0.67
ROE-0.43%
Fundamental Analysis

AI Price Forecasts

1 Week$0.86
1 Month$0.26
3 Months$2.50
1 Year Target$1.24

94E.F Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Zura Bio Limited (94E.F) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 67.52, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.24.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.99 and a market capitalization of 73M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

67.52RSI (14)
0.02MACD
14.74ADX
Revenue Growth
0.00%
Profit Growth
-0.69
24.81%
EPS Growth
-0.69
71.29%
Operating Margin
0.00%
11.89%
ROE
-43.35%
24.81%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 94E.FAnalyst Recommendations details for 94E.F are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

CEO

Robert Lisicki

Employees

30

Headquarters

4225 Executive Square, San Diego, CA

Founded

2023

Frequently Asked Questions

;